Dynamic changes of metabolic characteristics in neonatal intrahepatic cholestasis caused by citrin deficiency

Introduction: Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) is a pan-ethnic complicated inborn error of metabolism but the specific mechanism is not fully understood. Methods: A total of 169 patients with NICCD who have biallelic pathogenic SLC25A13 variants detected by targeted next-generation sequencing were collected. They were divided into the Newborn-screen Group and Clinical diagnosed Group depending on the newborn screening results. Amino acid and acylcarnitine profiles were measured by MS/MS. The total bile acids, blood amino acids and acylcarnitines, general biochemistry, blood count, and coagulation parameters were monitored every 2-3 months. We compared the differences in metabolic indices and their dynamic changes between these two groups. The Mann-Whitney test and orthogonal partial least squares discrimination analysis (OPLS-DA) were used for statistical analysis. Results: At the onset of NICCD, we found that the Clinical diagnosed Group had higher levels of intermediate products of the urea cycle, free carnitine, and short-chain and long-chain acylcarnitines than those in the Newborn-screen Group, but the levels of ketogenic/glucogenic amino acids and several medium-chain acylcarnitines were lower. Furthermore, concentrations of direct bilirubin, total bile acid, lactate, prothrombin time, and several liver enzymes were significantly higher while total protein, amylase, and hemoglobin were lower in the Clinical diagnosed Group than in the Newborn-screen Group. Dynamic change analysis showed that direct bilirubin, albumin, arginine, and citrulline were the earliest metabolic derangements to reach peak levels in NICCD groups, followed by acylcarnitine profiles, and finally with the elevation of liver enzymes. All abnormal characteristic metabolic indicators in the Newborn-screen Group came back to normal levels at earlier ages than the Clinical diagnosed Group. c.852_855del (41.2%), IVS16ins3kb (17.6%), c.615 + 5G > A (9.6%), 1638_1660dup (4.4%), and c.1177 + 1G > A (3.7%) accounted for 76.5% of all the mutated SLC25A13 alleles in our population. Conclusion: Argininosuccinate synthesis, gluconeogenesis, ketogenesis, fatty acid oxidation, liver function, and cholestasis were more severely affected in the Clinical diagnosed Group. The Newborn-screen Group had a better prognosis which highlighted the importance of newborn screening of NICCD.

Automated summary

This study explored the differences in metabolic indices between NICCD patients in the newborn-screen group and the clinical diagnosed group. The clinical diagnosed group showed more severe metabolic derangements and poorer prognosis. The findings highlight the importance of newborn screening for NICCD.